Viridian Therapeutics, Inc. Common Stock

VRDNNASDAQ • USD
30.87 USD
↗ 0.39 (1.28%)AT CLOSE (03:59 PM EST)
30.85
↘ 0.02 (0.06%)
POST MARKET (AS OF 04:15 PM EST)
Post Market
AS OF 04:15 PM EST
30.85
↘ 0.02 (0.06%)
🔴Market: CLOSED

Viridian Therapeutics, Inc. Common Stock (VRDN) trades at $30.87 per share. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". This is driven by a weak Piotroski F-Score of 1/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On the valuation front, VRDN trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Nov 13, 2026.

Open?$30.24
High?$30.96
Low?$29.81
Prev. Close?$30.48
Volume?1.2M
Avg. Volume?2.7M
VWAP?$30.55
Rel. Volume?0.45x
Bid / Ask
Bid?$28.00 × 100
Ask?$30.87 × 3.1K
Spread?$2.87
Midpoint?$29.44
Valuation & Ratios
Market Cap?3.5B
Shares Out?113.6M
Float?97.4M
Float %?86.0%
P/E Ratio?N/A
P/B Ratio?6.04
EPS?-$3.50
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Employees
252
Market Cap
3.5B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2014-06-18
Address
221 CRESCENT STREET
WALTHAM, MA 02453
Phone: 617.272.4600
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
37
Momentum?
90
Short Sent.?
50
Piotroski F-Score?1/9Weak
Altman Z-Score?2.04Grey
Confidence?55%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?17.49%High
Short Interest?17.0M
Days to Cover?9.1
Free Float97.4M
Avg Daily Volume1.9M
Settlement Date2026-10-30
Financial Health
Current Ratio?14.46Strong
Quick Ratio?14.46Strong
Cash Ratio?2.47Strong
Debt/Equity?0.63Moderate
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
30
6.04FAIR▾
P/S?
Peers
100
S&P
3
133.25HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-7.9CHEAP▾
EV/Sales?
Peers
100
S&P
3
140.51HIGH▾
Returns & Efficiency
ROE?
S&P
3
-68.4%WEAK▾
ROA?
S&P
3
-38.6%WEAK▾
Cash Flow & Enterprise
FCF?$-343444000
Enterprise Value?$3.7B
Fundamentals ratios updated end of day